Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Within the next month, Amgen Inc. AMGN is expected to report quarterly earnings at $4 per share on revenue of $6.26 billion, analysts say.

Amgen Options Traders Betting On Stock Rising This Much By April Expiration - Amgen (NASDAQ:AMGN)

Thanks to rising bond yields, investors have rotated out of many risky stocks this month. Bargain hunters may want to take advantage of this temporary pullback to load up on high-quality stocks.

This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips

RADNOR, Pa. , March 25, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN).

AMGN Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Investors of Securities Fraud Class Action Lawsuit

SAN DIEGO , March 25, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announced that it has filed a class action lawsuit seeking to represent purchasers or acquirers of Amgen Inc. (NASDAQ: AMGN) common stock between July 29, 2020 and April 27, 2022, inclusive (the "Class Period").  Captioned Roofers Local No.

AMGN NOTICE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

NEW YORK , March 24, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the "Class Period"), of the important May 12, 2023 . SO WHAT: If you purchased Amgen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN

Despite lower EPS in 4Q 2022 compared with 4Q 2021, Amgen's full-year 2022 financial results were strong. Amgen increased its free cash flow of $8381 million in 2021 by 4% in 2022 and thus, provided the opportunity for more distributions.

Amgen: Revenue Growth Potentials And Financial Performance

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN) ) common stock between July 29, 2020 and April 27, 2022, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)

Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.

Here's What is Driving Amgen (AMGN) Stock's Outperformance

Amgen expects to lay off >3% of its entire workforce before 1H 2023 - around 750 staff. Management says it has acted in response to rising interest rates and increasing pressure on drug pricing.

Amgen Announces More Layoffs - Why I'd Buy This Dip

Bristol-Myers

Comcast

Look no further if you want yield and distribution growth in a large-cap name with a blue-chip appeal. A simple screen using Marketbeat.com's dividend screener will turn up names like Comcast (NASDAQ: CMCSA), Bristol-Myers Squibb (NYSE: BMY), and Amgen (NYSE: AMGN), among others.

These Are The Top 3 Large Caps For Yield And Dividend Growth

SAN DIEGO--(BUSINESS WIRE)---- $AMGN #AMGN--Amgen Inc.

Amgen Inc. (AMGN) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Amgen Inc.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN) common stock between July 29, 2020 and April 27, 2022, inclusive (the “Class Period”). Investors suffering losses on their Amgen investments are encouraged to contact the Law Offices of Howard G.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)

Boeing

Travelers

Here are three Dow Jones stocks to keep on watch in the stock market now.

3 Dow Jones Stocks To Watch Today

Johnson & Johnson

UnitedHealth Group

With 60 years of consecutive annual raises, Johnson & Johnson is one of the most reliable dividend-paying stocks the world has ever known. Amgen is a successful biotechnology company that raised its dividend payout at a blazing pace in recent years and could do so again.

3 Dow Stocks Near 52-Week Lows That Look Like Bargains Now

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Amgen business and prospects, resulting in its stock trading at inflated prices.

AMGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Files Securities Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Lawsuit

RADNOR, Pa. , March 17, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN).

AMGEN CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Amgen Inc.

NEW YORK--(BUSINESS WIRE)---- $AMGN #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Amgen securities between July 29, 2020 and April 27, 2022, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.

Bronstein, Gewirtz & Grossman, LLC Notifies Amgen Inc. (AMGN) Investors of Class Action and to Actively Participate

Diamondback Energy

Gilead Sciences

Kraft Heinz

Walgreens

The Nasdaq had a dreadful 2022, down a stunning 33% for the year. While the tech-heavy index has started off 2023 much better, up 5.9% as of the close Thursday, many investors are extremely nervous, especially given the recent uncertainty with the banking industry.

The 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With a Spring Break Rally

Amgen Inc. on Thursday said it would lay off about 450 employees, or less than 2% of its workforce, as it faces increasing pressure from drug prices and high inflation.

Amgen to cut about 450 jobs in second round of layoffs this year

Amgen Inc said on Thursday it would cut 450 jobs, or less than 2% of its workforce, making it the company's second round of layoffs this year amid intensifying pressure on drug prices and high inflation.

Amgen to cut 450 jobs in second round of layoffs this year

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. (“Amgen”) (NASDAQ: AMGN). The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.

Attention Amgen Inc. (AMGN) Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against Amgen Inc. and Encourages Investors with Significant Losses to Contact the Firm

NEW YORK , March 16, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

AMGN ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amgen Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AMGN

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN) ) common stock between July 29, 2020 and April 27, 2022, inclusive (the “Class Period”). Amgen investors have until May 12, 2023 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Amgen Inc. (AMGN) Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN) ) common stock between July 29, 2020 and April 27, 2022, inclusive (the “Class Period”). Amgen investors have until May 12, 2023 to file a lead plaintiff motion. Investors suffering losses on their Amgen investments are encouraged to contact the Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Amgen Inc. (AMGN) Investors

Did you lose money on investments in Amgen Inc.?  If so, please visit Amgen Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Amgen Inc. (NASDAQ: AMGN)

News for Amgen Stock (AMGN)